Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»BioTech»Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line
    BioTech

    Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line

    Marie JonesBy Marie JonesMay 7, 2024Updated:May 8, 2024No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    “Nando”, a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position “Nando” not just as a leader in Lithuania but as a formidable player on the international stage.

    In a strategic enhancement of its management team, Nando welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at SEB and Citadele banks; Mindaugas Navickas, previously International Sales Manager at Teltonika Networks; ArÅ«nas Jusas, former General Manager at Timac AGRO; and GiedrÄ— MockienÄ—, who served as HR Manager at UAB Yara, are now integral parts of Nando’s leadership, aiming to spearhead ambitious development projects.

    To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, “Nando” has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, “Nando” exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

    Justinas Taruška, CEO of “Nando”, stated, “Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector’s value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents.” The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

    The inclusion of new management members, with their extensive international experience, underscores “Nando’s” commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

    Founded in 2007, “Nando” stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe’s leading R&D centers and partnerships with global research institutions, “Nando” has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The “Nando Group” proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

    Contact Information:
    Milda Gauliene
    Marketing specialist
    milda@nando.lt
    +37066475297

    SOURCE: Nando

    .

    View the original press release on newswire.com.

    Nando
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleHKTDC launches International Healthcare Week
    Next Article M&A Securities and NewParadigm Underwrites Rights Issue with Warrants for Siab Holdings Berhad’s Acquisition of Taghill

    Related Posts

    Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

    June 16, 2026

    Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

    June 9, 2026

    Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin’s Potential Across Metabolic Disease

    June 9, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.